Serum miR-455-5p and Cardiac Structure and Function Parameters in Patients With Hypertensive Heart Disease

Официальное название

Study on the Correlation Between Serum miR-455-5p Level and Cardiac Structure and Function Parameters in Patients With Hypertensive Heart Disease

Обзор

Hypertensive heart disease (HHD) is the leading cause of mortality and morbidity worldwide. In 2017, the prevalence of HHD worldwide was 217.9 per 100,000 people, an increase of 7.4% over 1990, which has brought huge financial burden and social and economic losses to the world. Therefore, HHD is a major public health challenge worldwide. In our previous studies, we found that miR-455-5p, a microRNA, could functioned as an inducer to promote cardiac hypertrophy. Because cardiac hypertrophy was a common phenomenon in patients with HHD, so it is interesting to clarify whether miR-455-5p could be employed as a marker to indicate the function and/or structure of heart in the development of HHD. Thus, the purpose of this study was to collect blood samples of hypertensive patients, as well as analysis the correlation between serum miR-455-5p level and cardiac function. The research could help doctors better predict the course of hypertensive heart disease and provide more effective treatments for different patients.

Подробное описание

The purpose of this study was to collect blood samples of hypertensive patients, in order to clarify the correlation between serum miR-455-5p level and cardiac function. Generally, by using q-PCR assay, miR-455-5p level of each participants will be collected. Besides, SBP, DBP, LVPWd, LVIDd, IVSTd was detected by echocardiography and EF, FS, LVMi, RWT level was further calculated by LVIDd, LVPWd and IVSTd. Finally, the correlation of miR-455-5p level of HHD patients and LVPWd, LVIDd, IVSTd, EF, FS, LVMi, RWT, SBP, DBP was analysed.

Первичные конечные точки

• Measurement of serum miR-455-5p level [Срок оценки: the miR-455-5p level is collected at week 0, 6, 12 and 24.]
• Measurement of LVPWd and LVPWs [Срок оценки: the LVPWd and LVPWs are collected at week 0, 6, 12 and 24.]
• Measurement of LVIDd and LVIDs [Срок оценки: the LVIDd and LVIDs are collected at week 0, 6, 12 and 24.]
• Measurement of IVSTd and IVSTs [Срок оценки: the IVSTd and IVSTs are collected at week 0, 6, 12 and 24.]
• Calculation of LVMi [Срок оценки: the LVMi is calculated at week 0, 6, 12 and 24.]
• Measurement of LVEF [Срок оценки: the EF is calculated at week 0, 6, 12 and 24.]
• Measurement of FS [Срок оценки: the FS is calculated at week 0, 6, 12 and 24.]
• SBP [Срок оценки: the SBP is collected at week 0, 6, 12 and 24.]
• DBP [Срок оценки: the DBP is collected at week 0, 6, 12 and 24.]

Критерии участия

Критерии включения

• 1\. age ≥18 years; 2. male or female; 3. systolic blood pressure ≥140mmHg or (and) diastolic blood pressure > 90mmHg; 4. history of hypertension>1year, NYHA grade I-IV

Критерии исключения

• hypertensive heart diseases patients with other metabolic diseases or congenital diseases were excluded from the study

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Модель наблюдения

Только случаи

Центры проведения

Китай · 1 центр

• the University of Hongkong-Shenzhen Hospital — Шэньчжэнь

Идентификаторы

NCT: NCT07033676 · caisd@hku-szh.org · 82300446 · 2022A1515111093 · RCBS20231211090745071

Первоисточники (государственные реестры)

• ClinicalTrials.gov (NIH, США)

Открыть это исследование на ClinicalTrials.gov ↗